JPH05230027A - Amide-substituted derivative of spiroindanylcamphor- sulfonyloxytocin antagonist - Google Patents

Abstract

Compounds of the formula: <CHEM> where R<1> is hydrogen or hydroxy and R<2> is a substituted amino group, a substituted heterocyclic ring or a substituted alkyl; are oxytocin and vasopressin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery, timing of parturition, uterine hyperactivity, endometriosis, hypertension, congestive heart failure, hyponatremia and cognitive disorders. Also disclosed are pharmaceutical compositions containing these compounds, methods of their use and methods of their preparation.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention provides novel compounds, novel compositions, methods of using them, and methods of making the same, such compounds generally being used as pharmacological agents in obstetrics and gynecology. Useful. The above pharmacological activity is useful for treating mammals. In addition, the compounds of the present invention treat premature birth, stop labor prior to Caesarean delivery,
And can be used to treat dysmenorrhea. At present, there is a demand in the area of obstetrics and gynecological therapy for such drugs.

[0002]

BACKGROUND OF THE INVENTION In the field of obstetrics, one of the most important problems is the treatment of preterm birth. A significant number of pregnancies over the 20th week of gestation experience preterm birth, which is a major cause of neonatal morbidity and mortality. Despite major advances in neonatal management, it is often desirable to retain the fetus in the womb.

Widely used labor resolution (uterine relaxation)
Agents include β ₂ -adrenergic agonists, magnesium sulfate, and ethanol. The main β ₂ -adrenergic agonist, ritodrine, causes maternal, tachycardia,
It causes a number of vascular and metabolic side effects including increased renin secretion, hyperglycemia (and reactive hypoglycemia in infants). Other β ₂ including terbutaline and albuterol
Adrenergic agonists have side effects similar to ritodrine. Magnesium sulphate at plasma concentrations above the therapeutic range of 4-8 mg / dL causes inhibition of cardiac conduction and neuromuscular transmission, respiratory depression, and cardiac arrest, and thus renal function is impaired. Not suitable. Ethanol is as effective as ritodrine in preventing preterm birth, but does not cause a corresponding reduction in the development of fetal dyspnea when ritodrine is administered.

It has been proposed that selective oxytocin antagonists are ideal labor resolution agents. Over the last few years, evidence has accumulated accumulating strongly that the hormone oxytocin is a physiological initiator of labor in several mammals, including humans. Oxytocin is believed to exert this effect in part by directly contracting the myometrium and in part by enhancing the synthesis and release of contractile prostaglandins from the endometrium / decidua.
These prostaglandins are also important in the cervical maturation process. By these mechanisms, the process of parturition (term and premature) is initiated by increased uterine sensitivity to oxytocin, partly as a result of a well-proven increase in the number of oxytocin receptors in uterine tissue. .. This "upregulation" of the oxytocin receptor and the enhancement of uterine sensitivity are likely due to the trophic effects of increasing plasma levels of estrogen towards the end of the month. By blocking oxytocin, both the direct (contractile) and indirect (enhanced prostaglandin synthesis) effects of oxytocin on the uterus can be blocked. Selective oxytocin blockers, or antagonists, appear to be more effective at treating preterm birth than conventional regimens. Moreover, since oxytocin has a major effect only on the uterus at term, such oxytocin antagonist compounds are expected to show few, if any, side effects.

The compounds of the present invention are further useful in the treatment of dysmenorrhea. This condition is characterized by periodic pain associated with menstruation during the ovulation cycle. Pain is believed to be due to uterine contractions and ischemia that appear to be mediated by the action of prostaglandins produced in the secretory intima. By blocking both the direct and indirect effects of oxytocin on the uterus, selective oxytocin antagonists may be more effective at treating dysmenorrhea than common regimens.

Accordingly, it is an object of the present invention to provide a substance which more effectively antagonizes the function of oxytocin in disease states in animals, preferably mammals, especially humans. Another object of the invention is to produce new compounds that inhibit oxytocin more selectively. Yet another object of the present invention is to provide a method of antagonizing the function of oxytocin in mammalian disease states. A further object of the present invention is to develop a method of preventing or treating oxytocin-related disorders of preterm labor and dysmenorrhea by antagonizing oxytocin.

[0007]

It has now been found that compounds of formula I are oxytocin antagonists and bind to the oxytocin receptor. When the oxytocin receptor binds to a compound of the invention, oxytocin is antagonized by being blocked from its receptor and thus unable to exert its biological or pharmacological effect. These compounds are useful in the treatment and prevention of oxytocin-related disorders in animals, preferably mammals, especially humans. These disorders are mainly preterm labor and dysmenorrhea. The compounds are further useful for stopping delivery preparation for Caesarean delivery.

The compounds of the present invention have the general formula:

[0009]

[Chemical 3] [Wherein R is H or alkylsulfonylalkyl, R ¹ is hydrogen or hydroxy, and R ² is N- (R
³ ) ₂ , one of Het-R ⁴ or Alk-R ⁵ , wherein R ³ is independently one or more hydrogens;
Cycloalkyl; pyrrolidinyl substituted by oxo, carboxyalkyl, or alkoxycarbonylalkyl; alkylamino, alkylcarbamate, alkylcarbonyl, alkylsulfonyl, alkylthio, alkoxycarbonyl, amino, aminocarbonyl, carboxyl, dialkylamino, dialkylaminoaryl, hydroxyl , Sulfhydryl, or 1 or 2
5 or 6 substituted or unsubstituted heterocyclic having 5 heteroatoms
A membered ring (wherein the heteroatom is N and the ring substituent is alkalkoxycarbonyl).
yl) which is alkyl substituted by He,
t is a heterocyclic 5- or 6-membered ring having 1 or 2 heteroatoms (wherein the heteroatom is N), R ⁴ is alkylsulfonyl, alkylsulfonylamino, alkylsulfonyloxy, alkylaminocarbonyl , Alkyl carbamate alkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonylalkyl, aminoalkylcarbonyl, alalkoxycarbonyl, carbonyl, dialkylaminocarbonyl, dialkylaminoalkylcarbonyl, diaminoalkylcarbonyl, halogenalkyl, halogenalkylcarbonyl, halogenalkoxycarbonyl , Hydroxy, hydroxyalkyl, hydroxyalkylcarbonyl, imidazolylalkylcarbonyl, imididinylalkylcarbonyl , Or phthalic imidate isoxazolidinyl alkyl, provided that, with respect to the Het-R ^4, Het is alkoxycarbonyl, alkoxycarbonylalkyl, not could be monosubstituted by any aralkoxycarbonyl, or hydroxy, Alk is alkyl, R ⁵
Are independently one or more R ⁶ or Het-R ⁷ , wherein R ⁶ is independently one or more alkyl carbamate; a substituted imidazolyl or pyrrolidinyl ring (wherein the ring substituent is Is alkyl or alkoxycarbonylalkyl, alkylcarbamate cycloalkyl, alkylcarbonylaminoalkylsulfonyl, alkylimidazolylthio, alkylimididinylthio,
Alkyl imidazolyl alkyl thio, alkyl imididinyl alkyl thio, alkyl pyrrolidinyl thio, alkyl pyrrolidinyl alkyl thio, alkyl sulfonyl, alkyl sulfonyl amino, alkyl sulfonyl alkyl amino, alkoxy carbonyl, alkoxy carbonyl alkyl amine, alkoxy carbonyl alkyl carbonyl amine, alkoxy carbonyl alkyl. Sulfonylamine, amino, aminocarbonyl, aminoalkylcarbonylamino, aminocarbonylalkylsulfonyl, aminocarbonylalkylcarbonylamino, alalkoxy, alalkoxycarbonyl, alalkylcarbamate, arylcarbamate, arylcarbamatecarbonylamino, arylcarbamatealkylcarbonylamino Carboxyalkyl amino, carboxyalkyl carbonyl amino, carboxyalkyl alkylsulfonylamino, cyano, cyanoalkyl carbonyl, dialkylamino alkylcarbonylamino,
Or oxo and is) but alkylcarbonylamino substituted by, however, with respect to R ^6, R ⁶ is alkoxycarbonyl, alkyl carbamate, alkylsulfonyl, aralkyl carbamates, aralkoxy, amino, aminocarbonyl, or oxo Het is as defined above; R ⁷ is one or more alkyls; imidazolinylalkylcarbonyl; imidazolinylalkylcarbonylamino; oxo; pyrrolidinylalkylcarbonyl A pyrrolidinylalkylcarbonylamino substituted with one or more alkylcarbamate, alkylcarbamate alkylcarbonyl, alkylsulfonylalkyl, amino, alkalkoxyalkyl or oxo, or an alkyl Is an amino, however, Het-
For R ⁷ , Het is alkyl, alkylamino,
Cannot be monosubstituted by dialkylamino or oxo]
And a pharmaceutically acceptable salt thereof.

The salts embraced by the term "pharmaceutically acceptable salts" refer to the non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts are listed below: Acetate Lactobionate Benzenesulfonate Laureate Benzoate Malate Bicarbonate Maleate Bisulfate Mandelate Bisartrate Mesylate Borate Methyl Bromide Methyl nitrate Calcium edetate Sulfate methyl camsylate Mucate Carbonate Napsylate Chloride Nitrate Clavulanate N-Methylglucamine Citrate Oxalate Dihydrochloride Pamoate (embonate) Edetate Palmitate Edisilate Pantothenate Estrate Phosphate / Diphosphate Esylate Polygalactouronate Fumarate Salicylate Glucceptate Stearate Gluconate Subacetate Glutamate Succinate Glycolylsanilate Tannate Hexylresorcine Tartrate Hydrabamine Theocrate Hydrobromide Tosylate Hydrochloride Triethiodide Hydroxynaphthoate Valerate Iodide Isethionate Lactate , An amount of a drug or formulation that elicits a biological or medical response in an animal or human.

The term "alkyl" refers to a total of 1-10
By straight or branched chain alkanes, alkenes, and alkynes having one carbon atom or having one or more degrees of unsaturation at any position on any number of chains within this range.

The term "aryl" means phenyl.

The term "cycloalkyl" refers to a total of 3
It means an alkane, alkene, or alkyne cyclic ring having one or more degrees of unsaturation at any position of the ring having ˜8 carbon atoms.

Either "alkyl" or "aryl", or their prefixes, is the name of a substituent (eg alkalkoxyaryloxy).
Whenever in oxy)), they are intended to be inclusive of the restrictions indicated above for “alkyl” and “aryl”. A specified number of carbon atoms (eg C1-
10) independently indicates the number of carbon atoms of the alkyl or cyclic alkyl moiety, or the alkyl moiety of a larger substituent in which alkyl is represented by its prefix.

The term "oxo" refers to the substituent = O.

The term "halogen" includes iodine, bromine, chlorine and fluorine.

The term "preterm birth" refers to the elimination from the uterus of a viable infant prior to the normal termination of pregnancy, or especially pregnancy.
It means the start of labor associated with the disappearance and expansion of the cervix before the week. It may be accompanied by vaginal bleeding or membrane rupture.

The term "dysmenorrhea" means painful menstruation.

The term "cesarean section" means an incision in the abdominal and uterine walls for fetal delivery.

The term "substituted" is considered to include multiple degrees of substitution with the designated substituents.

The ability of the compounds of formula I to antagonize oxytocin makes them useful as medicaments against mammals, especially against humans, for the treatment and prevention of disorders involving oxytocin. Examples of such disorders include preterm birth and especially dysmenorrhea. These compounds have also been found to be useful in stopping labor in preparation for Caesarean delivery.

Because of the known relationship between vasopressin and oxytocin, the compounds of this invention are also useful as vasopressin antagonists. Vasopressin antagonists are useful in treating or preventing disease states associated with vasopressin disorders, including their use as diuretics and their use in congestive heart failure.

The compounds of the present invention may be used in tablets, capsules (including timed-release and sustained-release formulations, respectively), pills,
It may be administered in oral dosage forms such as powders, granules, elixirs, tinctures, suspensions, syrups and emulsions.

Similarly, they may be administered in intravenous (bolus and infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the desired compound is to
It can be used as a synthetic agent).

Dosage regimens using the compounds of the present invention include:
Patient type, species, age, weight, sex, and medical condition;
It is selected according to the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof used. A routine practitioner or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

The oral dose of the present invention, when used for the desired effect, is orally in the range of about 0.3 to 6.0 gm / day. Intravenously, 0.1 to about 10 during constant rate injection
The most preferred range is mg / min. The compounds of the present invention may be administered once a day or may be administered at a total daily dose of 2-3 times daily.
Or, it is beneficial to administer in 4 divided doses. Furthermore, preferred compounds of the present invention may be administered in intranasal form via suitable intranasal vehicle topical use or via the transdermal route, using those in the form of transdermal skin patches well known to those of ordinary skill in that art. For administration in the form of transdermal delivery systems, dose administration is, of course, continuous rather than intermittent throughout the dosing regimen.

In the method of the present invention, the compounds detailed herein make up the active ingredient and are suitably selected for the intended dosage form, ie oral tablet, capsule, elixir, syrup, etc., and are conventional. It is generally administered in admixture with a suitable drug diluent, excipient, or carrier (collectively referred to herein as "carrier" material) consistent with formulation practice.

For example, for oral administration in the form of tablets or capsules, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. . Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia gum, tragacanth gum or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Be done. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. As the disintegrant, starch, methyl cellulose,
Examples include agar, bentonite, xanthan gum and the like.

The compounds of the present invention further include small unilamellar vesicles,
Liposomes such as large unilamellar vesicles and multilamellar vesicles. It can be administered in the form of a delivery system. Liposomes are composed of various phospholipids such as cholesterol, stearylamine, or phosphatidylcholines.

The compounds of the present invention may be supplied using monoclonal antibodies as the individual carriers to which the compound molecules are attached. The compounds of the present invention can be coupled with soluble polymers as targeted drug carriers. Such polymers include polyvinylpyrrolidone substituted with palmitoyl residues, pyran copolymers, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamide-phenol, or polyethylene oxide polylysine. In addition, the compounds of the present invention are useful in certain biodegradable polymers useful in achieving controlled release of drugs, such as polylactic acid, polyepsiloncaprolactone, polyhydroxybutanoic acid, polyorthoesters,
It may be combined with crosslinked or amphiphilic block copolymers of polyacetals, polydihydropyrans, polycyanoacrylates, and hydrogels.

The compounds of formula I are prepared according to the following reaction schemes (all of which can be modified as above), and the examples or readily available starting materials, reagents and modifications thereof using conventional synthetic procedures. It can be easily prepared. In these reactions it is also possible to use variants which are known per se to the person skilled in the art but are not mentioned in more detail.

Most preferred compounds of the present invention are any or all of those specifically mentioned in these examples. However, these compounds should not be construed as synthesizing only the types of compounds contemplated by this invention, as any combination of this compound or any portion thereof may itself form a compound of this invention. . The following examples further illustrate details for the preparation of compounds of this invention. Those skilled in the art will readily understand that known modifications of the conditions and steps of the following production procedures can be used to produce these compounds. All temperatures are degrees Celsius unless otherwise noted.

[0033]

[Chemical 4]

[0034]

[Chemical 5]

[0035]

[Chemical 6] Example 4

[0036]

[Chemical 7] Example 5

[0037]

[Chemical 8] Example 6

[0038]

[Chemical 9] Example 8

[0039]

[Chemical 10] Reaction Scheme, Part 2

[0040]

[Chemical 11] Reaction Scheme, Part 3

[0041]

[Chemical 12] Reaction Scheme, Part 3 Continuation

[0042]

[Chemical 13]

[0043]

[Chemical 14] Reaction Scheme, Part 3 Continuation

[0044]

[Chemical 15] Reaction Scheme, Part 4

[0045]

[Chemical 16]

[0046]

[Chemical 17] Reaction Scheme, Part 5

[0047]

[Chemical 18] Reaction Scheme, Part 5 Continuation

[0048]

[Chemical 19] Reaction Scheme, Part 6

[0049]

[Chemical 20] Reaction Scheme, Part 7

[0050]

[Chemical 21] Reaction Scheme, Part 7 Continuation

[0051]

[Chemical formula 22]

[0052]

[Chemical formula 23] Reaction Scheme, Part 7 Continuation

[0053]

[Chemical formula 24] Example A

[0054]

[Chemical 25] Endo- (1S) -1 '(((2-amino-7,7-dimethylbicyclo (2.2.1) -hept-1-yl)-
Methyl) -sulfonyl) spiro (1H-indane-1,
4'-piperidine) di-t-butyl dicarbonate (31g, 0.14mo
1, obtained from Aldrich), and bis (2-chloroethyl) amine hydrochloride (21.6 g, 0.12 mol, A
ldrich) at ambient temperature with stirring under CH ₂ Cl ₂
Triethylamine (12.8 g, 0.127 mol) combined in (250 ml) and added dropwise over 15 minutes.
Processed in. After 1 hour, another 1.5 ml triethylamine was added. After a total of 2.5 hours, the mixed solution was CH ₂
Pour onto a silica gel column packed with Cl ₂ : hexane (1: 1) and elute with CH ₂ Cl ₂ . The product fractions were combined and evaporated to dryness in vacuo to give N, N-bis (2-
Chloroethyl) -t-butyl-carbamate was obtained.

A solution of indene (10.3 g, 89 mmol) in dry tetrahydrofuran (THF, 18 ml) cooled in an ice bath and kept in a nitrogen blanket was charged with bis (trimethylsilyl) amide lithium (over 15 minutes. Aldrich, 177m dissolved in THF
l 1.0 M solution; 177 mmol) was added. The mixture was stirred in the cold for 30 minutes, then N, N-bis (2-chloroethyl) -t-butyl-carbamate (21.2 g, 88 m) with stirring in an ice bath for 15 minutes.
ol). The mixture was stirred under nitrogen for 2 hours in the cold, 30 minutes at ambient temperature, then evaporated in vacuo to a foam. CH ₂ Cl ₂ was added and the resulting mixture was poured onto a silica gel column packed with 40% hexane dissolved in CH ₂ Cl ₂ . The column was washed with 40% hexane in CH ₂ Cl ₂ and then C
Elution with H ₂ Cl ₂ and evaporation of the product fractions in vacuo gave 1 ′-(t-butyloxycarbonyl) -spiro (indene-1,4′-piperidine).

1 '-(t-Butyloxycarbonyl) -spiro (indene-1,4'-piperidine) (16 g, 56 mmo) dissolved in ethyl acetate (250 ml).
l) was stirred for 30 minutes in an ice bath and saturated with HCl (g). The mixture was evaporated to dryness. Ethyl acetate was added, vacuum removed 3 times, the residue was triturated with diethyl ether, filtered and spiro hydrochloride (1H-indene-1,
4'-piperidine) was produced. The hydrochloride salt was slurried in aqueous sodium bicarbonate solution and extracted with CH ₂ Cl ₂ to give the free base. The organic layer was separated, dried over sodium sulfate, filtered, evaporated and dried in vacuo to give spiro (1H-indene-1,4′piperidine).

Spiro (1H-indene-1,4'-piperidine) (308 mg, 1.66 mmol) and (+)-10-camphorsulfonyl chloride (418 mg,
1.66 mmol) was mixed in CH ₂ Cl ₂ and treated with triethylamine (0.23 ml). The mixture was stirred at ambient temperature for 15 minutes, then poured onto a silica gel column and eluted with 1: 1 CH ₂ Cl ₂ : hexane.
The product fractions were combined, evaporated to dryness in vacuo, (1S)
-1 '-(((7,7-dimethyl-2-oxobicyclo- (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H-indene-1,4'-piperidine) Obtained as a solid, which was recrystallized from petroleum ether and dried under vacuum at ambient temperature overnight.

Dissolved in pyridine (500 ml) (1
S) -1 ′-(((7,7-Dimethyl-2-oxobicyclo- (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H-indene-1,4′-piperidine ) (30 g, 0.075 mol) in an oil bath at 70 ° C.
Heated (inside). Hydroxylamine hydrochloride (30
g) was added in 3 portions over about 20 minutes. Two hours later,
An additional 10 g of hydroxylamine hydrochloride was added (1
Over 0 minutes). After an additional 30, 40, and 50 minutes, an additional 3 g of hydroxylamine hydrochloride was added. After another 30 minutes, the mixture was poured into water (2 L) and extracted 3 times with ethyl acetate (300 ml once). The organic layers were combined, washed with 1N HCl (total 600 mL), dried over sodium sulfate, filtered, evaporated and dried in vacuo. EtOH (anhydrous; ca. 250 mL) was added to the resulting concentrated syrup and the solution was left at ambient temperature overnight. The mixture was filtered and the filtrate was boiled to about 80 mL. After standing, the mixture is filtered again,
It was boiled and boiled down to about 20 mL. After filtering three times, the filtered solids were mixed to obtain (1S) -1 ′-(((7,7-
Dimethyl-2-oxyiminobicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H
-Indene-1,4'-piperidine) (28g) was obtained.

Freshly prepared activated Raney nickel catalyst in water (about 30 g) was allowed to settle and the water decanted. Absolute ethanol (300 mL) was added and the mixture was stirred and reprecipitated. The solvent was decanted. 150
Wash decanting was also performed twice more with mL of ethanol. (1S) -1 '-(((7,7-Dimethyl-2-oxyiminobicyclo- (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H-
Indene-1,4′-piperidine) (30 g) was stirred in a mixture of absolute ethanol (450 mL) and 2-methoxyethanol (900 mL), nitrogen was bubbled through the suspension / solution, Raney nickel catalyst. Was added. The mixture was hydrogenated under 50 psi overnight. TLC (9:
CH ₂ : Cl ₂ MeOH 1 (silica gel) 1 showed the reaction was complete. The catalyst was removed by filtration, the filtrate was evaporated and dried in vacuo. 7 g of crude solid (27 g)
Divide into batches, each batch with methylene chloride (about 200m
L) dissolved in silica (700 in a 100 mm column)
g chromatography, flash chromatography on 8% (v / v) methanol dissolved in methylene chloride) to give 200 mL fractions. The exo isomers of the title amine were obtained in roughly fractions 5-7 and the desired endo isomers in roughly fractions 8-16. TLC (silica)
Elution with 8% methanol-methylene chloride and phosphomolybdic acid staining. The combined product fractions are evaporated to dryness,
Title compound (4.5g from each 7g lot, total about 18g)
Was obtained as a colorless solid.

The abbreviations used in the examples are: TEA = triethylamine DIEA = diisopropylethylamine BOP = benzotriazol-yloxytris (dimethylamino) phosphonium hexafluorophosphate THF = tetrahydrofuran DMF = dimethylformamide LAH = lithium hydride aluminum TFA = trifluoroacetic acid HPLC method a = 15 min, linear gradient (95: 5 a: 0 from B: 100 of a: B until) a - 0.1 containing volume percent of TFA H ₂ O B = CH ₃ CN flow rate 2.0 mL / min 12cm C18 reversed phase column UV detection containing 0.1% by volume of TFA (215 nm) TLC was performed on 20cm plates coated with silica gel (250 [mu]) purchased from Analtech.

Example 1 (1S) -1 '-(((7,7-Dimethyl-2-endo- (4-nitrophenyloxycarbonylamino) -bicyclo (2.2.1) hept-1-yl) -Methyl) sulfonyl) spiro (1H-indene-1,4'-piperidine) The product of Example A [3.47 mmol] and 4-nitrophenyl chloroformate [3.64 mmol] were added to T
Mixed in HF. The reaction mixture was treated with triethylamine [4.54 mmol] and stirred for 2 hours. The reaction mixture was concentrated to dryness and the resulting residue was purified on a silica gel column eluting with 1% ethyl acetate in methylene chloride. The product fractions were combined, concentrated and dried in vacuo. The title compound was obtained from ether as a white solid.

Example 2 The product of Example 1 [0.278 mmol] and (benzyloxycarbonyl) piperazine acid [0.334 mm
were mixed in DMF. The reaction mixture was treated with triethylamine [0.401 mmol] and stirred for 2 hours. The reaction mixture was concentrated and dried, and the resulting residue was dissolved in CH ₂ Cl ₂ . The solution was placed on a silica gel column and eluted with 5% methanol in CH ₂ Cl ₂ and then 96/4 / 0.4 CH ₂ Cl ₂ / methanol / acetic acid. The product fractions were combined, evaporated to dryness. The title compound was obtained from ether as a white solid and dried in vacuum overnight.

Melting point: 90-120 ° C. NMR: Consistent with structure HPLC: Purity> 98% FAB MS: M ⁺ + H-693.6 CHN: C ₃₇ H ₄₈ N ₄ O ₇ S.0.20C ₄ H ₁₀ O.
Calculated CHN as 0.25H ₂ O: Calculated: C, 63.74; H, 7.15; N, 7.87 Found: C, 63.78; H, 7.08; N, 7. 81 Example 3

[0064]

[Chemical formula 26] Using the product of Example 1 [0.196 mmol] and triethylamine [0.438 mmol], (benzyloxycarbonyl) piperazine acid was converted into N-α- (t-butoxycarbonyl) -L-lysine [0.217 mmol].
Instead of, the procedure of Example 2 was performed. The chromatography eluent was 5% methanol dissolved in CH ₂ Cl ₂ and then 96/4 / 0.4 CH ₂ Cl ₂ / methanol / acetic acid. A white solid was obtained from ether. This white solid was dissolved in ethyl acetate, cooled to 0 ° C. and treated with a saturated solution of HCl in ethyl acetate. The reaction mixture was stirred for 30 minutes then concentrated to dryness. The title compound was obtained from ether as a white solid and dried in vacuum overnight.

Melting point: 80-205 ° C. NMR: Consistent with structure HPLC: Purity> 98% FAB MS: M ⁺ + H = 575.3 (free base) C ₃₀ H ₄₆ N ₄ O ₅ S.HCl.0.30 mmol C _Four
Elemental analysis calculated as H ₈ O ₂ · 0.90H ₂ O: Calculated value: C, 57.30; H, 7.89; N, 8.57 Measured value: C, 57.30; H, 7.61 N, 8.55 Example 4

[0066]

[Chemical 27] Using the product of Example 1 [0.174 mmol] and triethylamine [0.250 mmol], replacing (benzyloxycarbonyl) piperazine acid with N-isopropylcyclohexylamine [0.209 mmol],
The procedure of Example 2 was carried out. The chromatography eluent was 5% methanol dissolved in CH ₂ Cl ₂ . The title compound was obtained from ether as a white solid and dried in vacuum overnight.

Melting point: 71-85 ° C. NMR: Consistent with structure HPLC: Purity> 96% FAB MS: M ⁺ + H = 570.4 Elemental analysis calculated as C ₃₃ H ₅₁ N ₃ O ₃ S: Calculated value: C, 69.55; H, 9.02; N, 7.37 Found: C, 69.53; H, 9.08; N, 7.29 Example 5

[0068]

[Chemical 28] Using the product [0.244 mmol] of Example 1 and triethylamine [0.52 mmol], (benzyloxycarbonyl) piperazine acid was converted into 3-amino-1- (1).
The procedure of Example 2 was carried out substituting -methoxycycarbonyl-2-methylpropyl) -pyrrolidin-2-one [0.26 mmol]. Chromatographic eluent is C
5% methanol dissolved in H ₂ Cl _2, was used with 2% methanol was dissolved 1% methanol was dissolved in CH ₂ Cl _2, and CH ₂ Cl _2. The title compound was obtained from ether as a white solid and dried in vacuum overnight.

Melting point: 85-121 ° C. NMR: Consistent with structure HPLC: Purity> 91% FAB MS: M ⁺ + H = 643.4 C ₃₄ H ₅₀ N ₄ O ₆ S.0.45H ₂ O

[0070]

[Chemical 29] Using the product of Example 1 [0.172 mmol], triethylamine [0.453 mmol] and substituting (benzyloxycarbonyl) piperazine acid for L-histidinol dihydrochloride [0.206 mmol], the procedure of Example 2 was followed. Carried out. Chromatographic eluent is CH ₂ Cl
5% methanol dissolved in ₂ , then 95/5/0.
5 of CH ₂ Cl ₂ / methanol / aqueous ammonia was used. The title compound was obtained from ether as a white solid and dried in vacuum overnight.

Melting point: 90-193 ° C. NMR: Consistent with structure HPLC: Purity> 98% FAB MS: M ⁺ + H = 570.4 C ₃₀ H ₄₃ N ₅ O ₄ S.0.25 C ₄ H ₁₀ O.0 .30
Elemental analysis calculated as H ₂ O: Calculated value: C, 62.71; H, 7.83; N, 11.8
0 Found: C, 62.73; H, 7.79; N, 11.7.
5 Example 7

[0072]

[Chemical 30] Using the product [0.180 mmol] and triethylamine [0.458 mmol] of Example 1 and substituting (benzyloxycarbonyl) piperazine acid for 4- (dimethylamino) benzylamine dihydrochloride [0.208 mmol]. The procedure of Example 2 was carried out. Chromatography eluant 5% methanol dissolved in CH ₂ Cl _2, then with 3% methanol dissolved in CH ₂ Cl _2.
The title compound was obtained from ether as a white solid and dried in vacuum overnight.

Melting point: 82-110 ° C. NMR: Consistent with structure HPLC: Purity> 95% FAB MS: M ⁺ + H = 579.4 Elemental analysis calculated as C ₃₃ H ₄₆ N ₄ O ₃ S: Calculated: C, 68.48; H, 8.01; N, 9.68 Found: C, 68.25; H, 8.00; N, 9.68 Example 8

[0074]

[Chemical 31] Step 1: Histamine [13.3 mmol] and methyl vinyl sulfone [4.6 mmol] were mixed in methanol and stirred for 4 hours. The reaction mixture was concentrated to dryness and the resulting residue was dissolved in CH ₂ Cl ₂ . CH ₂ C
The ₁₂ solution was poured onto a silica gel column, 93/7/0.
Elute with 7 of CH ₂ Cl ₂ / methanol / aqueous ammonia. The product fractions were combined, evaporated to dryness in vacuo, 4-
(2- (N- (2-methanesulfonylethyl) amino)
Ethyl) imidizole was obtained.

Step 2: The product of Example 1 [0.188
mmol], triethylamine [0.228 mmol]
Was followed by substituting (benzyloxycarbonyl) piperazine acid for 4- (2- (N- (2-methanesulfonylethyl) amino) ethyl) imidizole [0.368 mmol] using the procedure of Example 2. The chromatography eluent was 3% methanol dissolved in CH ₂ Cl ₂ .
Then 95/5 / 0.5 CH ₂ Cl ₂ / methanol /
Ammonia water was used. The title compound was obtained from ether as a white solid and dried in vacuum overnight.

[0076] mp: 76~161 ℃ NMR: Consistent with structure HPLC: ^{purity> 99% FAB MS: M +} + H = 646.2 C 32 H 47 N 5 O 5 S 2 · 0.15 C 4 H 10 · 0 .15
Elemental analysis calculated as CH ₂ Cl ₂ · 0.45 H ₂ O: Calculated: C, 58.03; H, 7.39; N, 10.3
3 Found: C, 57.98; H, 7.32; N, 10.4.
9 Example 9

[0077]

[Chemical 32] Step 1: Mix histamine [13 mmol] and ethyl acrylate [4.61 mmol] in methanol,
It was stirred for 12 hours. The reaction mixture was concentrated to dryness and the resulting residue was dissolved in CH ₂ Cl ₂ . CH ₂ Cl
Pour the ₂ solutions onto a silica gel column, 93/7 / 0.7
Of CH ₂ Cl ₂ / methanol / aqueous ammonia. The product fractions were combined, evaporated to dryness in vacuo, 4-
(2- (N- (2-ethoxycarbonylethyl) amino) ethyl) imidizole was obtained.

Step 2: (1S) -1 '-(((7,7-
Dimethyl-2-endo- (4-nitrophenyloxycarbonylamino) -bicyclo (2.2.1) hept-1
-Yl) -methyl) sulfonyl) spiro (1H-indene-1,4'-piperidine) [0.69 mmol] and triethylamine [1.56 mmol] were used to convert (benzyloxycarbonyl) piperazine acid into 4- (2- (N
-(2-Ethoxycarbonylethyl) amino) ethyl)
Instead of imidizole [1.42 mmol], L-36
The procedure for 8,646 was performed. The chromatography eluent was 5% methanol dissolved in CH ₂ Cl ₂ .
Then 95/5 / 0.5 CH ₂ Cl ₂ / methanol /
Ammonia water was used. A white solid was obtained from ether and dried under vacuum overnight. This white solid was mixed with 1.95M sodium hydroxide dissolved in methanol. The reaction mixture was stirred for 72 hours then concentrated to dryness. The resulting residue was partitioned between ethyl acetate and water. The ethyl acetate layer was dried over sodium sulfate, filtered, and the filtrate was concentrated and dried. 91/10/1/1 CH ₂ Cl ₂ /
The residue was purified by silica gel column, eluting with methanol / water / acetic acid. The purified product fractions were combined, concentrated and dried. The title compound was obtained from ether as a white solid and dried in vacuum overnight.

Melting point: 63-132 ° C. NMR: Consistent with structure HPLC: Purity> 99% FAB MS: M ⁺ + H = 612.2 C ₃₂ H ₄₅ N ₅ O ₅ S.0.20 C ₄ H ₁₀ O.0 .80
Elemental analysis calculated as C ₂ H ₄ O ₂ 1.35 H ₂ O: Calculated: C, 59.10; H, 7.63; N, 10.0
2 Found: C, 59.11; H, 7.24; N, 10.0.
7 Example 10 End- (1S) -1 ′-(((2- (L-2- (4-
Imidazoleacetylamino) glutaramyl) amino-7,7-dimethylbicyclo (2.2.1) hept-1
-Yl) -methyl) sulfonyl) spiro (1H) -indan-1,4'-piperidine)

[0080]

[Chemical 33] Step 1: End- (1S) -1 '-(((2- (L-2
-(T-butoxycarbonylamino) glutaramyl)
Amino-7,7-dimethylbicyclo- (2.2.1)-
Hept-1-yl) -methyl) sulfonyl) spiro (1
H) -Indan-1,4'-piperidine) In an oven-dried flask in nitrogen, acetonitrile (3 mL) was added to endo- (1S) -1 '-(((2-amino-7,7-dimethylbicyclo (2 1.2.1) Hept-
1-yl) -methyl) sulfonyl) spiro (1H) -indan-1,4′-piperidine) (50 mg, 0.12
5 mmol), L-N- (t-butoxycarbonyl)-
Glutamine (30.7 mg, 0.125 mmol), and benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate s
Equalog (55 mg, 0.125 mmol) was dissolved. Diisoproprethylamine (100 μL) was added to make the solution basic. After HC (silica, methylene chloride (9) -methanol (1)) showed a new spot, the reaction mixture was concentrated to an oil. The oil was dissolved in methylene chloride-ether (1: 3) and the solution washed with sodium bicarbonate (saturated, aqueous), water, potassium hydrogen sulfate (10%), and salt (saturated, aqueous).
The organic layer was dried over sodium sulfate. After filtration, the solution was concentrated to an oil, which was used as a solvent in methylene chloride-
Purified by silica "flash" chromatography using methanol (9: 1). The product fraction was concentrated to an oil. After adding hexane: ether, the mixture was concentrated under reduced pressure to give the title compound as a white foam.

NMR (CDCl ₃ ): Consistent with structure HPLC: Purity> 79.5% Elemental analysis calculated as C ₃₃ H ₅₀ N ₄ O ₆ S.0.25 H ₂ O: Calculated: C, 62.39 H, 8.01; N, 8.82 Found: C, 62.37; H, 7.99; N, 8.73 Step 2: Hydrochloric acid endo- (1S) -1 '-(((2- L-
(2- (Amino) glutaramylamino) -7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H-indan-1,4 ′
-Piperidine) endo- (1S) -1 '-(((2-
(L-2- (tert. Butoxycarbonylamino) glutaramyl) amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methylsulfonyl) spiro (1H) -indane-1,4 The'-piperidine) was dissolved in ethyl acetate (5 ml) and cooled to -5 ° C. This solution is placed under a nitrogen atmosphere and hydrogen chloride gas is added to 1
Aerated for 0 minutes. The solvent was removed under reduced pressure. Ether was added and removed under reduced pressure to give the title compound as a white solid.

HPLC: Purity> 92% Mass spectrum: M ⁺ + H 532.4 (free base) NMR (CDCl ₃ ): Consistent with structure C ₂₈ H ₄₂ N ₄ O ₄ S.HCl.1.35 H ₂ O. 0.
Elemental analysis calculated for 25 hexanes: Calculated: C, 57.79; H, 8.09; N, 9.14 Found: C, 57.80; H, 8.16; N, 9.14 Step 3 : End- (1S) -1 '-(((2- (L-2
-(4-imidazoleacetylamino) glutaramyl) amino-7,7-dimethylbicyclo (2.2.1)
Hept-1-yl) -methyl) sulfonyl) spiro (1
H) -Indan-1,4′-piperidine) In an oven-dried flask (50 ml) under nitrogen, dimethylformamide (1 mL) was added with endo- (1S) -hydrochloric acid.
1 ′-(((2-L- (2-amino) -glutaramylamino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H)
-Indan-1,4'-piperidine) (56.7 mg,
0.0001m), 4-imidazole hydrochloride (20m
g, 0.000124m), hydrochloric acid 1-ethyl-3- (3
-Dimethylaminopropyl) carbodiimide (30m
g, 0.15 mmol) and 1-hydroxybenzotriazole hydrate (20 mg, 0.15 mmol) were dissolved. Triethylamine (120 μl) was added to make the solution basic (pH 9). A white solid separated. 1
After stirring for 8 hours, the solvent was removed under reduced pressure. The residue was dissolved in ether-methylene chloride (3: 1). The opaque solution was washed with sodium bicarbonate (saturated, aqueous) and brine. After dehydration with sodium sulfate, the solution was filtered and concentrated to an oil. The product is methylene chloride as a solvent
Purified by silica "flash" chromatography using methanol (9: 1), collecting product fractions and concentrating to an oil. Ether-hexane was added and removed under reduced pressure to give the title compound as a white foam.

HPLC: Purity> 94% Mass spectrum: M ⁺ + H 639.6 NMR (CDCl ₃ ): Consistent with structure Elemental analysis calculated as C ₃₃ H ₄₆ N ₆ O ₅ S.1.30 H ₂ O: Calculation Value: C, 59.85; H, 7.40; N, 12.6
9 Found: C, 59.66; H, 7.36; N, 12.9.
7 Example 11 End- (1S) -1 ′-(((2- (L-2- (1-
Methyl-4-imidazoleacetylamino) glutaramyl) amino-7,7-dimethylbicyclo (2.2.
1) hept-1-yl) -methyl) sulfonyl) spiro (1H-indan-1,4′-piperidine)

[0084]

[Chemical 34] Endo- (1S) -hydrochloric acid was added to dimethylformamide (1 ml) in an oven-dried flask (50 ml) under nitrogen.
1 ′-(((2-L- (2-amino) -glutaramylamino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H)
-Indan-1,4'-piperidine) (57 mg, 0.
1 mmol), 1-methyl-4-imidazole hydrochloride (20 mg, 0.1 mmol), 1-ethyl-3-hydrochloride.
(3-Dimethylaminopropyl) carbodiimide (30
mg, 0.15 mmol) and 1-hydroxybenzotriazole hydrate (20 mg, 0.15 mmol) were dissolved. Triethylamine (120 μl) was added to make the solution basic (pH 9). A white solid separated. After stirring for 3 days, the solvent was removed under reduced pressure. The residue was dissolved in ether-methylene chloride (3: 1). The opaque solution was washed with sodium bicarbonate (saturated, aqueous) and brine. The organic layer was dried over sodium sulfate, filtered,
Concentrated to an oil. The product material was isolated by "flash" silica chromatography using methylene chloride, methanol, and aqueous ammonia (9: 1: 1) as solvents. The product fraction was collected and concentrated to an oil. After adding ether: hexane, the solvent was removed under reduced pressure to give the title compound as a white foam.

HPLC: Purity> 90% Mass spectrum: M ⁺ + H 653.3 NMR (CDCl ₃ ): Consistent with structure Analytical value for C ₃₄ H ₄₈ N ₆ O ₅ S.1.55 H ₂ O: Calculated value. : C, 59.98; H, 7.57; N, 12.3
5 Found: C, 60.00; H, 7.33; N, 12.0.
5 Example 12 End- (1S) -1 ′-(((2- (L-2- (β-
Alaninylamino) glutaramyl) amino) -7,7
-Dimethylbicyclo (2.2.1) hept-1-yl)
-Methyl) sulfonyl) spiro (1H) -indane-
1,4'-piperidine)

[0086]

[Chemical 35] Step 1: End- (1S) -1 '-(((2- (L-2
-(Β-tert-Butoxycarbonylaminoalaninylamino) glutaramyl) amino) -7,7-dimethylbicyclo (2.2.1) -hept-1-yl) -methyl) sulfonyl) spiro (1H) -indane -1,4 '
-Piperidine) Endo- (1S) -hydrochloric acid in dimethylformamide (2 ml) in an oven-dried flask (50 ml) under nitrogen.
1 ′-(((2-L- (2-amino) glutaramylamino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl-sulfonyl) spiro (1H)-
Indan-1,4'-piperidine) (110 mg, 0.
19 mmol), β-N- (tert-butoxycarbonyl) -alanine (37.8 mg, 0.2 mmol),
Hydrochloric acid 1-ethyl-3- (3-dimethylaminopropyl)
Carbodiimide (60 mg, 0.3 mmol), and 1
-Hydroxybenzotriazole hydrate (40 mg,
0.0003 m) was dissolved. Triethylamine (12
0 μl) was added to make the solution basic (pH 9).
A white solid separated. After stirring for 18 hours, the solvent was removed under reduced pressure. The residue was dissolved in ether-methylene chloride (3: 1). The opaque solution was washed with sodium bicarbonate (saturated, aqueous), water, potassium hydrogen sulfate (10%, aqueous), and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to an oil. The product material was purified by "flash" silica chromatography using methylene chloride: methanol (9: 1) as solvent.
The product fractions were collected and concentrated to give an oil. After addition of ether: hexane it was removed under reduced pressure to give the title compound as a white foam.

HPLC: Purity> 98% Mass spectrum: M ⁺ + H 702.4 NMR (CDCl ₃ ): Consistent with structure Analyzed as C ₃₆ H ₅₅ N ₅ O ₇ S: Calculated: C, 61.60; H, 7.90; N, 9.98 Found: C, 61.51; H, 8.02; N, 9.62 Step 2: Hydrochloric acid endo- (1S) -1 '-(((2- ( L
-2- (β-aminoalaninylamino) glutaramyl) amino) -7,7-dimethylbicyclo (2.2.
1) hept-1-yl) -methyl) sulfonyl) spiro (1H) -indan-1,4′-piperidine) endo- (1S) -1 ′-(((2- (β-tert.
Butoxycarbonylaminoalaninylamino) glutaramyl) amino-7,7-dimethylbicyclo (2.2.
1) Hept-1-yl) -methyl-sulfonyl) spiro (1H) -indan-1,4′-piperidine was dissolved in ethyl acetate (5 ml) and cooled to −5 ° C. The solution was placed under a nitrogen atmosphere and hydrogen chloride gas was bubbled through for 10 minutes. The solvent was removed under reduced pressure. Ether was added and removed under reduced pressure to give the title compound as a white foam.

HPLC:> 97% purity Mass spectrum (free base): M ⁺ + H 602.3
(Free base) NMR (CDCl ₃ ): Consistent with structure C ₃₁ H ₄₇ N ₅ O ₅ S.HCl.1.30 H ₂ O.0.
25 Analytical value as ethyl acetate: Calculated value: C, 56.21; H, 7.75; N, 10.2
4 Found: C, 56.23; H, 7.50; N, 10.2.
4 Example 13 endo- (1S) -1 ′-(((2- (L-2- (methylmalonylamino) glutaramyl) amino) -7,7
-Dimethylbicyclo (2.2.1) hept-1-yl)
-Methyl) sulfonyl) spiro (1H) -indane-
1,4'-piperidine)

[0089]

[Chemical 36] Endo- (1S) -1′-hydrochloric acid in methylene chloride (3 ml) in an oven dry flask (50 ml) under nitrogen.
(((2-L- (amino) -glutaramylamino-
7,7-Dimethylbicyclo (2.2.1) hept-1-
Iyl) -methyl) sulfonyl) spiro (1H) -indane-1,4′-piperidine (56.7 mg, 0.1 mm
ol) was dissolved. Monomethylmalonyl chloride (13.7
μl, 0.1 mmol) was added. After stirring for 2 minutes, triethylamine (100 ml) was added to make the solution basic (pH 9). TLC (silica, methylene chloride:
Methanol 9: 1)) showed a new spot. The solvent was removed under reduced pressure. "Flush" the sticky material with methylene chloride: methanol (9: 1) as solvent
Purified by silica chromatography. The title compound was isolated and concentrated to an oil which was treated with hexane-ether to give a foam.

HPLC: Purity> 95% Mass spectrum: M ⁺ + H 631.5 NMR (CDCl ₃ ): Consistent with structure Analytical value for C ₃₂ H ₄₆ N ₄ O ₇ S.0.45 H ₂ O: Calculated value. : C, 60.15; H, 7.40; N, 8.77 Actual value: C, 60.15; H, 7.23; N, 8.78 Example 14 End- (1S) -1'- (((2- (L-2- (2-
(Methylsulfonyl) ethylamino) glutaramyl)
Amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H)
-Indan-1,4'-piperidine)

[0091]

[Chemical 37] In an oven-dried flask (50 ml), methanol (2 mL) was added with endo- (1S) -1 ′-(((2-
L- (amino) glutaramylamino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H) -indan-1,4 ′
-Piperidine) (57 mg, 0.1 mmol) was dissolved. Methyl vinyl sulfone (10 mg, 8.3 μL,
0.1 mmol), and triethylamine (20 μL)
Was added using a syringe. 2 hours later (2μ
L) It was necessary to add methyl vinyl sulfone. The reaction was stirred at room temperature overnight. The solvent was removed under reduced pressure to produce a sticky material. The material was purified by silica "flash" chromatography using methylene chloride: methanol (9: 1) as solvent. The product fractions were collected and concentrated to give a sticky material. After addition of ether-hexane, these solvents were removed under reduced pressure to isolate the title compound as a white foam.

HPLC: Purity> 94% Mass spectrum: M ⁺ + H 637.3 NMR (CDCl ₃ ): Consistent with structure Analyzed as C ₃₁ H ₄₈ N ₄ O ₆ S ₂ .0.5 H ₂ O: Calculated. Value: C, 57.64; H, 7.65; N, 8.68 Found: C, 57.67; H, 7.34; N, 8.96 Example 15 End- (1S) -1 '. -(((2- (L-2- (4-
Imidazoleacetylamino) histidinyl) amino-
7,7-Dimethylbicyclo (2.2.1) hept-1-
Yl) -methyl) sulfonyl) spiro- (1H) -indane-1,4'-piperidine)

[0093]

[Chemical 38] Endo- (1S) -hydrochloric acid was added to dimethylformamide (1 mL) in an oven dry flask (50 mL) under nitrogen.
1 '-(((2- (L-N-histidinyl) amino-
7,7-Dimethylbicyclo (2.2.1) hept-1-
(Il) -methyl) sulfonyl) spiro- (1H) -indan-1,4'-piperidine) (20 mg, 0.124
mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (30 mg, 0.15 mm
ol) and 1-hydroxybenzotriazole hydrate (20 mg, 0.15 mmol) were dissolved. Add triethylamine (150 μL) to make the solution basic (pH
9). After stirring overnight, the solvent was removed under reduced pressure.
The product material was isolated by "flash" silica chromatography using methylene chloride-methanol-aqueous ammonia (9: 1: 1) as the solvent. The product fractions were collected and concentrated to give the title compound as a light brown foam.

[0094] HPLC: purity> 97% Mass ^{spectrum: M + + H 648.3 NMR (} CDCl 3): as Consistent with structure _{C 34 H 45 N 7 O 4} S · 0.70 H 2 O · 0.60 ethyl ether Analytical value for: Calculated value: C, 62.02; H, 7.49; N, 13.9.
1 Found: C, 61.99; H, 7.34; N, 13.9.
2 Example 16 endo- (1S) -1 ′-(((2,2- (2- (methylsulfone) ethyl)-(1-methyl-4-imidoazadeacetyl) amino) -7,7-dimethyl Bicyclo (2.
2.1) Hept-1-yl) -methyl) sulfonyl) spiro- (1H) -indan-1,4′-piperidine)

[0095]

[Chemical Formula 39] Step 1: End- (1S) -1 '-(((2- (2-
(Methylsulfonyl) ethyl) amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro- (1H) -indane-1,
4'-piperidine) endo- (1S) -1'- dissolved in methanol (2 mL) in a 20 mL flask.
(((2-amino-7,7-dimethylbicyclo (2.
2.1) Hept-1-yl) -methyl) -sulfonyl)
Spiro- (1H) -indan-1,4'-piperidine)
(100 mg, 0.25 mmol), and methyl vinyl sulfone (22 mg, 20.5 μL, 0.22 mmo
The solution of l) was stirred overnight. The solvent was removed under reduced pressure. The product was isolated by "flash" chromatography using methylene chloride: methanol (9: 1) as solvent. The product fractions were collected and concentrated. Treatment with hexane: ether gave the title compound as a white foam.

HPLC: Purity> 99% Mass spectrum: M ⁺ + H 509.2 NMR (CDCl ₃ ): Consistent with structure Analytical value for C ₂₆ H ₄₀ N ₂ O ₄ S.0.25 H ₂ O: Calculated value. : C, 60.84; H, 7.95; N, 5.46 Found: C, 60.79; H, 7.78; N, 5.55 Step 2: Oven dry flask in nitrogen (50 ml). In dimethylformamide (1 mL) with endo- (1
S) -1 '-(((2-2- (methylsulfonyl) ethyl) amino-7,7-dimethylbicyclo (2.2.1)
Hept-1-yl) -methyl-sulfonyl) spiro-
(1H) -Indan-1,4'-piperidine) (50m
g, 0.1 mmol), 1-methyl-4-imidazole hydrochloride (20 mg, 0.1 mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (30 mg, 0.15 mmol), and 1- Hydroxybenzotriazole hydrate (20mg, 0.15mm
ol) was dissolved. After triethylamine (100 μL) was added to make the solution basic (pH 9), a white solid was separated. After stirring overnight, the solvent was removed under reduced pressure. The oil was dissolved in ether-methylene chloride (3: 1).
The opaque solution was washed with sodium bicarbonate (saturated, aqueous), water, potassium hydrogen sulfate (10%, aqueous), and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to an oil. The product was obtained by "flash" chromatography using methylene chloride, methanol, aqueous ammonia (9: 1: 1) as solvent. The product fractions were collected and concentrated. After adding ether: hexane, these were removed under reduced pressure to give the title compound as a white foam.

HPLC: Purity> 98% Mass spectrum: M ⁺ + H 631.3 NMR (CDCl ₃ ): Consistent with structure Analytical value for C ₃₂ H ₄₆ N ₄ O ₅ S ₂ 1.30 H ₂ O: Calculated. Value: C, 58.74; H, 7.49; N, 8.56 Found: C, 58.72; H, 7.10; N, 8.41 Example 17 End- (1S) -1 '. -(((2- (2- (N-butoxycarbonylpiperidine) acetyl) amino-7,7
-Dimethylbicyclo (2.2.1) hept-1-yl)
-Methyl) sulfonyl) spiro- (1H) -indane-
1,4'-piperidine)

[0098]

[Chemical 40] Endo- (1S) -1 ′ to dimethylformamide (1 mL) in an oven dry flask (50 ml) under nitrogen.
-(((2-amino-7,7-dimethylbicyclo (2.
2.1) Hept-1-yl) -methyl-sulfonyl) spiro- (1H) -indan-1,4'-piperidine (5
0 mg, 0.125 mmol), 2- (N-tert.
Butoxycarbonylpiperidine) acetic acid (40 mg, 0.
16 mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (30 mg, 0.15
mmol) and 1-hydroxybenzotriazole hydrate (20 mg, 0.15 mmol) were dissolved. Triethylamine (50 μL) was added to make the solution basic (p
H 9). After 1 hour, the solvent was removed under reduced pressure and the residue was dissolved in ether-methylene chloride (3: 1). The organic solution was washed with sodium bicarbonate (saturated, aq), water, potassium hydrogen sulfate (10%, aq), and brine. The solution was dried over sodium sulfate, filtered and concentrated to an oil. The product is methylene chloride as a solvent:
Purified by "flash" chromatography with methanol (9: 1). The product fractions were collected and concentrated. After addition and removal of hexane: ether, the title compound was obtained as a white foam.

HPLC: Purity> 96% Mass spectrum: M ⁺ + H 685.5 NMR (CDCl ₃ ): Consistent with structure Analytical value as C ₃₇ H ₅₆ N ₄ O ₆ S.0.3 H ₂ O: Calculated value. : C, 64.37; H, 8.26; N, 8.12 Actual value: C, 64.37; H, 8.13; N, 8.12 Example 18 End- (1S) -1'- (((2- (Dimethylaminoglycinylglycinyl) amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro- (1H) -indane-1,4 '-Piperidine

[0100]

[Chemical 41] Step 1: End- (1S) -1 ′-(((2- (ter
t-butoxycarbonylglycinylglycinyl) amino-
7,7-Dimethylbicyclo (2.2.1) hept-1-
(Iyl) -methyl) sulfonyl) spiro- (1H) -indan-1,4'-piperidine) Dimethylformamide (1 mL) was placed in an oven dried flask (50 ml) under nitrogen. End- (1
S) -1 '-(((2-amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl-sulfonyl) spiro- (1H) -indane-1,4'- Piperidine (50 mg, 0.125 mmol), N-ter
t. Butoxycarbonylglycinylglycine (29m
g, 0.125 mmol), 1-ethyl-3- (3 hydrochloride)
-Dimethylaminopropyl) carbodiimide (30m
g, 0.15 mmol) and 1-hydroxybenzotriazole hydrate (20 mg, 0.15 mmol) were added and the mixture was stirred until a solution was formed. . After 1 hour, the reaction was completed and the solvent was removed under reduced pressure. The gummy residue was dissolved in ether-methylene chloride (3: 1). The opaque solution was washed with sodium bicarbonate (saturated, aqueous), water, potassium hydrogen sulfate (10%, aqueous), and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to an oil. The product was isolated by "flash" chromatography using methylene chloride: methanol (9: 1) as solvent. The product fraction was collected and concentrated to an oil. Ether-hexane was added and removed under reduced pressure to give the title compound as a foam.

HPLC: Purity> 98% Mass spectrum: M ⁺ + H 617 NMR (CDCl ₃ ): Consistent with structure C ₃₂ H ₄₈ N ₄ O ₆ S.0.3 Analytical value as hexane: Calculated: C, 63 .30; H, 8.24; N, 8.66 Found: C, 63.26; H, 8.26; N, 8.84 Step 2: Hydrochloric acid endo- (1S) -1 '-((( 2- (glycinylglycinyl) amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro- (1H) -indan- (2.4 ')-piperidine ) Endo- (1S) -1 ′-(((2- (tert-butoxycarbonylglycinylglycinyl) amino-7,7-
Dimethylbicyclo (2.2.1) hept-1-yl)-
Methyl) sulfonyl) spiro- (1H) -indane-
1,4'-piperidine was dissolved in ethyl acetate (5 mL) and cooled to -5 ° C. This was placed under a nitrogen atmosphere and hydrogen chloride gas was bubbled through for 10 minutes. The solvent was removed under reduced pressure. Ether-hexane was added and then removed under reduced pressure to give the title compound as a white foam.

[0102] HPLC: purity> 98% Mass ^{spectrum: M + + H 517.3 NMR (} CDCl 3): Consistent with structure _{C 27 H 40 N 4 O 4} S · HCl · 0.80 H 2 O · 0.
25 Analytical value as ethyl acetate: Calculated value: C, 57.03; H, 7.62; N, 9.50 Found value: C, 57.06; H, 7.35; N, 9.68 Step 3 : Endo- (1S) -1 ′-(((2- (glycinylglycinyl) amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro- (1H) -Indan- (2.4 ′)-piperidine was dissolved in 1% acetic acid / methanol (3 mL). Formaldehyde (50 μL, 37% aqueous solution)
Then sodium cyanoborohydride (20 mg) was added. After stirring overnight, the reaction mixture was cooled to 0 ° C. and sodium bicarbonate (10 mL, saturated, aqueous) was added. The resulting suspension was extracted with ethyl acetate. The ethyl acetate was washed with brine and dried over sodium sulfate. After filtration and concentration, the oil was methylene chloride-methanol (9:
Purified by "flash" chromatography using 1). The purified material fractions were concentrated and then removed by addition of ether-hexane to give the title compound as a foam.

HPLC: Purity> 96% Mass spectrum: M ⁺ + H 545.4 NMR (CDCl ₃ ): Consistent with structure Analyzed as C ₂₉ H ₄₄ N ₄ O ₄ S.0.95 H ₂ O: Calculated. : C, 61.99; H, 8.23; N, 9.87 Found: C, 62.00; H, 7.90; N, 9.85 Example 19

[0104]

[Chemical 42] 2-Amino-N- [1-[[(2,3-dihydrospiro [1H-indene-1,4'-piperidine] -1'hydrochloric acid
-Yl) sulfonyl] methyl] -7,7-dimethylbicyclo [2.2.1] hept-2-yl] -4 (methylsulfonyl) -butanamide (150 mg, 0.265 m
mol), and 4-imidazole carboxylic acid (49 m
g, 0.304 mmol) in nitrogen at room temperature for 12 m
6 dissolved in 1 of dry N, N'-dimethylformamide
1 mg (0.318 mmol) of hydrochloric acid 1-ethyl-3-
Mixed with (3-dimethylaminopropyl) carbodiimide, and 43 mg (0.318 mmol) of 1-hydroxybenzotriazole. The pH of the reaction mixture was adjusted to 9 with triethylamine and the resulting solution was stirred for 6 hours. Further, 0.5 equivalent of imidazolecarboxylic acid, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, and 1-hydroxybenzotriazole were added, and the stirring was continued for further 48 hours. The reaction mixture was diluted with methylene chloride (150 ml) and the resulting solution was saturated sodium bicarbonate solution (2x40 ml), 10% citric acid solution (2x40 m).
l), and brine, then dried (magnesium sulfate) and concentrated to yield 100 mg of crude material. The crude material was dissolved in methanol and filtered through glass wool. Vydac C-18 column (4.5x
The filtrate was purified by preparative HPLC chromatography using 150 mm, water-acetonitrile-1% trifluoroacetic acid, 45 min gradient). Homogeneous fractions containing product were pooled and concentrated. The residue was dissolved in ethyl acetate from which the title compound was precipitated as a white amorphous solid.

NMR (CDCl ₃ ): Consistent with structure; HPLC:> 99% purity at 214 nm; FAB MS: 674 (M ⁺ + H); C ₃₃ H ₄₇ N ₅ O ₆ S ₂ .1.0 trifluoroacetic acid. Elemental analysis calculated as: C, 53.35; H, 6.14; N, 8.89 Found: C, 53.16; H, 6.04; N, 8.89 Example 20

[0106]

[Chemical 43] 2-Amino-N- [1-[[(2,3-dihydrospiro [1H-indene-1,4'-piperidine] -1'hydrochloric acid
-Yl) sulfonyl] methyl] -7,7-dimethylbicyclo [2.2.1] hept-2-yl] -4- (methylsulfonyl) -butanamide (150 mg, 0.265
(mmol) was suspended in 5 ml of methylene chloride. The pH of the suspension was adjusted to 9 with triethylamine.
Next, to this homogeneous solution was added benzyloxycarbonyl-b.
-Alanine (71 mg, 0.398 mmol), hydrochloric acid 1
-Ethyl-3- (3-dimethylaminopropyl) carbodiimide (86 mg, 0.450 mmol), and 1-
Hydroxybenzotriazole (61 mg, 0.450
mmol) respectively. The reaction mixture was stirred at room temperature under nitrogen for 24 hours. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between ethyl acetate (100 ml) and sodium bicarbonate solution. The phases were separated and the organic phase was washed with saturated sodium bicarbonate solution (3x40ml), 10% citric acid solution, and brine, then dried (magnesium sulfate) and concentrated to give 200mg of a solid. Recrystallisation from methanol gave an analytical sample as a white amorphous solid: NMR (CDCl ₃ ): Consistent with structure; HPLC:> 99% purity at 214 nm; FAB MS: 771 (M ⁺ + H); C Elemental analysis calculated as ₃₉ H ₅₃ N ₄ O ₈ S ₂ : Calcd: C, 60.83; H, 6.94; N, 7.27 Found: C, 60.59; H, 7.01; N, 7.34 Example 21

[0107]

[Chemical 44] 2-Amino-N- [1-[[(2,3-dihydrospiro [1H-indene-1,4'-piperidine] -1'hydrochloric acid
-Yl) sulfonyl] methyl] -7,7-dimethylbicyclo [2.2.1] hept-2-yl] -4 (methylsulfonyl) -butanamide (150 mg, 0.265 m
mol) in 2.5 ml of methanol,
Treated with a solution of 2.65 ml of ethyl acrylate dissolved in ml of methanol. The pH of the reaction mixture was adjusted to neutral with 1 eq triethylamine. The reaction mixture was then stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between ethyl acetate (100 ml) and water. The phases were separated, the organic phase was washed with water and brine, then dried (magnesium sulfate) and concentrated to yield 80 mg of oil. This material was purified by preparative thin layer chromatography on silica gel (chloroform-
Methanol development, 96: 4, v / v; 1 from silica gel
0% methanol - to give tetrahydrofuran isolation), and recrystallized from methanol to give a white solid: NMR (CDCl _3): Consistent with structure. Confirm presence of solvent; HPLC: Purity> 214% at 214 nm; FAB MS: 666 (M ⁺ + H); Elemental analysis calculated as C ₃₃ H ₅₁ N ₃ O ₇ S ₂ · 1.1 Tetrahydrofuran: Calculated: C, 60.27; H, 8.09; N, 5.64 Found: C, 60.28; H, 7.89; N, 5.34 Example 22

[0108]

[Chemical 45] 2-Amino-N- [1-[[(2,3-dihydrospiro [1H-indene-1,4'-piperidine] -1'hydrochloric acid
-Yl) sulfonyl] methyl] -7,7-dimethylbicyclo [2.2.1] hept-2-yl] -4 (methylsulfonyl) -butanamide (100 mg, 0.176 m
mol) was suspended in 5 ml methylene chloride and subsequently treated with methylchlorosulfonylacetate (45 mg) and triethylamine sufficient to adjust the pH of the reaction mixture to about 10. The reaction mixture was protected from moisture and stirred at room temperature for 18 hours. A further equivalent amount of methyl chlorosulfonyl acetate was added and stirring was continued for another 6 hours. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between ethyl acetate (100 ml) and water. The phases were separated and the organic phase was washed with water and brine then dried (magnesium sulfate) and concentrated to give 102 mg of crude material as a solid. This material was purified by flash column chromatography on silica gel (chloroform-methanol development, 96: 4, v / v) and triturated with ether-petroleum ether to give the analyte: NMR ( CDCl ₃ ): Consistent with structure; HPLC:> 95% purity at 214 nm; FAB MS: 702 (M ⁺ + H); Elemental analysis calculated as C ₃₁ H ₄₇ N ₃ O ₉ S ₃ : Calcd: C, 53. .04; H, 6.74; N, 5.99 Found: C, 52.95; H, 6.91; N, 5.80 Example 23

[0109]

[Chemical 46] 2- [1-[[(2,3-Dihydrospiro [1H-indene-1,4'-piperidin] -1'-yl) sulfonyl] methyl] -7,7-dimethylbicyclo [2.2.
1] Hept-2-yl] cyanoacetamide (108m
g, 0.230 mmol) dissolved in 8 ml of tetrahydrofuran, methyl vinyl sulfone (29 mg, 0.
272 mmol) and 0.5 ml of 1,8-diazabicyclo [5.4.0] -undec-7-ene. The reaction mixture was protected from moisture and heated to reflux for 23 hours. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between ethyl acetate (100 ml) and water. The phases are separated,
The organic phase is saturated sodium bicarbonate solution (3 x 50 ml),
Wash with 10% citric acid solution (1 x 50 ml) and brine. The dried (magnesium sulfate) organic extract was concentrated to yield 100 mg of crude material as a solid.
This material was flash column chromatographed on silica gel (hexane-ethyl acetate, 1: 2 v /
Purified by v) to give the title compound as a white solid: NMR (CDCl ₃ ): Consistent with structure. Confirmation of the presence of solvent; HPLC: Purity> 214% at 214 nm; FAB MS: 682 (M ⁺ + H); Elemental analysis calculated as C ₃₂ H ₄₇ N ₃ O ₇ S ₃ .0.8 H ₂ O: Calculation Value: C, 55.21; H, 7.04; N, 6.03 Found: C, 55.21; H, 6.81; N, 5.82 Example 24

[0110]

[Chemical 47] 2-tert-butyloxycarbonylamino-N-
[1-[[(2,3-Dihydrospiro [1H-indene-1,4'-piperidin] -1'-yl) sulfonyl]
Methyl] -7,7-dimethylbicyclo [2.2.1] hept-2-yl] -4- (methylsulfonyl) -thiobutanamide (150 mg, 0.220 mmol)
It was mixed with methyl glycinate hydrochloride (21 mg, 0.242 mmol) and mercuric chloride (242 mmol) dissolved in a 1: 1 dry N, N-dimethylformaldehyde-tetrahydrofuran solvent mixture. The pH of the reaction mixture was raised to 11 with triethylamine and the mixture was heated to 60 ° C. overnight. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between ethyl acetate (100 ml) and water. The phases were separated and the organic phase was saturated sodium bicarbonate solution (3
x 50 ml), and brine. The dried (magnesium sulfate) organic extract was concentrated to give the crude material as a bright red solid. This material was subjected to flash column chromatography on silica gel (chloroform-methanol-concentrated aqueous ammonia eluent, 90: 10: 1 v /
v) to give the title compound 75mg as a yellow solid: NMR (CDCl _3): Consistent with structure. Evidence of solvent; HPLC: Purity> 214% at 214 nm; FAB MS: 682 (M ⁺ + H); C ₃₆ H ₅₆ N ₄ O ₈ S ₂ · 1.2 H ₂ O.0.05 C.
Elemental analysis calculated as HCl ₃ : Calculated: C, 56.63; H, 7.71; N, 7.33 Found: C, 56.26; H, 7.35; N, 7.76 Examples 25

[0111]

[Chemical 48] 2-tert-butyloxycarbonylamino-N-
[1-[[(2,3-Dihydrospiro [1H-indene-1,4'-piperidin] -1'-yl) sulfonyl]
Methyl] -7,7-dimethylbicyclo [2.2.1] hept-2-yl] acetamide (1.3 g, 2.48 m
mol) in 15 ml of tetrahydrofuran,
Treated with 752 mg (1.86 mmol) Lawesson's reagent. The reaction mixture was heated at reflux for 2 hours then concentrated in vacuo. The pH of the reaction mixture was raised to 11 with triethylamine and the mixture was heated at 60 ° C. overnight.
The reaction mixture was concentrated under reduced pressure and a portion of the residue was purified by preparative thin layer chromatography on silica gel (hexane-ethyl acetate, elution 7: 3 v / v) to homogenize. After trituration with ether-petroleum ether, the title compound was obtained as a white solid: NMR (CDCl ₃ ): Consistent with structure; HPLC: Purity> 214% at 214 nm; FAB MS: 576 (M ⁺ + H); C ₃₀ H Elemental analysis calculated as ₄₅ N ₃ O ₄ S ₂ : Calcd: C, 62.57; H, 7.87; N, 7.29 Found: C, 62.79; H, 8.09; N, 7.00 Example 26

[0112]

[Chemical 49] Endo- (1S) dissolved in acetonitrile (8 mL)
-1 '-(((2-amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H) -indan-1,4'-piperidine (403 mg. 1 mmol) and 1-Fmoc-4-C
bz-2-piperazinecarboxylic acid (535 mg; 1.1
mmol) in a stirred solution of benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate (487 mg; 1.1 mmol).
Was added. Diisopropylethylamine with a pH of 9
Was added until. After stirring at room temperature for 15 hours, the solution was concentrated, then redissolved in ethyl acetate and washed with water, 1M HC
1 and brine successively. The organic extract was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The product is flash chromatographed (99: 1 C
H ₂ Cl ₂ : CH ₃ OH) to give 860 mg
Was obtained as a white foam (46%).

10% Pd / C (50 mg) was added to a solution containing the above material (400 mg; 0.46 mmol) dissolved in ethanol (100 mL). The mixture was connected to a Parr hydrogen generator and shaken at 60 psi. After 15 hours, the mixture was filtered and concentrated. Flash chromatography (95: 5 CH ₂ Cl ₂ : CH
_The residue was purified with ₃ OH) to give a white foam (170
mg; 50%) was obtained. A portion of this material (150 mg;
0.20 mmol) and diisopropylethylamine (28 mg; 0.22 mmol) were dissolved in methylene chloride (4 mL) at 0 ° C. Methanesulfonyl chloride (25m
g; 0.22 mmol) was added. After stirring at room temperature for about 18 hours, piperidine (2 mL) was added. After stirring for an additional 2 hours, the opaque reaction mixture was filtered under reduced pressure and then concentrated. Flash chromatography (95: 5
Purification with CH ₂ Cl ₂ : CH ₃ OH) gave a white foam (108 mg; 91%).

3: 1 acetonitrile: dimethylformamide (4 mL) dissolved in the above material (81 mg;
132 mmol), 2-imidazole acetic acid (27 mg;
0.164 mmol), and BOP reagent (73 mg;
0.164 mmol) was added diisopropylethylamine until the pH was 8. About 18 hours later,
The dark solution was concentrated under reduced pressure. Preparative HPLC (Vyd
ac C18 reverse phase column; 1 "x 10"; gradient 95:
_{5~20: 80 H 2 O: CH} 3 CN, 0.1% TF
The residue was purified by A-containing; flow rate 10 mL / min; 60 min gradient) to give the title compound. The purified material was lyophilized from 1,4-dioxane to give a white solid (8 mg; 8%).

C ₃₄ H ₄₈ N ₆ O ₆ S ₂ 1.40 TFA
As calculated: C, 51.36; H, 5.79; N, 9.77 Found: C, 51.42; H, 5.71; N, 9.53 HPLC: 100%; ¹ H NMR: Consistent with structure; FAB MS: 701 (M ⁺ + H); Example 27

[0116]

[Chemical 50] Step A: endo- (1S) -1 ′-(((2-amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -dissolved in methylene chloride (9 mL) at 0 ° C. Methyl) sulfonyl) spiro (1H) -indane-1,4 ′
-Piperidine (906 mg; 2.25 mmol) and diisopropylethylamine (291 mg; 2.25 mm
2) bromide dissolved in methylene chloride.
A solution of bromoacetyl (453 mg; 2.25 mmol) was added. The solution was warmed to room temperature for 3 hours and then concentrated under reduced pressure. The product material was purified by flash chromatography (9: 1 methylene chloride: diethyl ether) to give 1.1 g of white foam (93%).

1 dissolved in ethyl alcohol (1 mL)
To a stirred solution containing 31 mg of the above bromide (0.25 mmol) was added diisopropylethylamine (38.8).
mg; 0.30 mmol) and ethyl-2-mercaproacetate (36.1 mg; 0.30 mmol). After 2 hours, the solution was directly loaded onto a Vydac C18 reverse phase HPLC column (1 ″ × 10 ″; gradient 95: 5-3).
_{0:70 H 2 O: CH 3 CN} , 0.1% TFA -containing; was applied to 60 min gradient); flow rate 10 mL / min. The purified fractions were concentrated and then lyophilized from 1,4-dioxane to give the title compound as a white solid (108mg; 77%).
Got as.

C ₂₉ H ₄₂ N ₂ O ₅ S ₂ · 0.15 TFA
Analytical value as: Calculated value: C, 60.68; H, 7.33; N, 4.83 Measured value: C, 60.76; H, 7.38; N, 5.03 TLC: Rf = 0 _{.40 (98: 2 CH 2 Cl} 2:
CH ₃ OH) HPLC: 94.8%; ¹ HNMR: Consistent with structure; FAB MS: 563 (M ⁺ + H); Step B: Sulfide as described in Step A (113 mg;
20 mmol) was dissolved in methylene chloride (1.5 mL) and cooled to 0 ° C. Meta-chloroperbenzoic acid (40.
6 mg; 0.20 mmol, assuming 85% purity) was added and then the solution was warmed to room temperature. After 1.5 hours, the solution was concentrated. Preparative HPLC (Vydac C18 reverse phase column; 1 "x10"; gradient 95: 5 to 20: 80H.
₂ O: CH ₃ CN, containing 0.1% TFA; flow rate 13.5
The residue was purified by (mL / min; 60 min gradient). 1,4
-After lyophilization from dioxane, the title compound was obtained as a white solid (24 mg; 20%).

C ₂₉ H ₄₂ N ₂ O ₆ S ₂ .0.20 TFA
Analytical value as: Calculated value: C, 58.69; H, 7.07; N, 4.66 Found value: C, 58.78; H, 7.13; N, 4.95 HPLC: 98.9. %; ¹ HNMR: Consistent with structure; FAB MS: 579 (M ⁺ + H); Step C: Material from Step B (25 mg; 0.04 mmo) dissolved in ethyl alcohol (1 mL) at 0 ° C.
A stream of ammonia gas was introduced into the stirred solution of l). 10
After minutes, the reaction vessel was sealed and the solution warmed to room temperature. After 15 hours, the solution was concentrated and purified by preparative HPLC (Vydac C
18 reverse phase column; 1 "x 10"; gradient 95: 5-2
_{0:80 H 2 O: CH 3 CN} , 0.1% TFA -containing; residue was purified by 60 min gradient); flow rate 13.5 mL / min. After lyophilization from 1,4-dioxane, the title compound was obtained as a white solid (22 mg; 92%).

C ₂₇ H ₃₉ N ₃ O ₅ S ₂ · 0.45 TFA
Analytical value as: Calculated value: C, 55.75; H, 6.62; N, 6.99 Found value: C, 55.60; H, 6.62; N, 6.77 HPLC: 97%; ¹ H NMR: Consistent with structure; FAB MS: 550 (M ⁺ + H); Example 28.

[0121]

[Chemical 51] Endo- (1S) dissolved in methylene chloride (25 mL)
-1 '-(((2-amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H) -indan-1,4'-piperidine (300 mg. 0.745 mmol) in a stirred solution of 2-bromoacetyl chloride (68_L; 0.82 mmol).
And then diisopropylethylamine (130_L;
0.745 mmol) was added. After 15 minutes at room temperature, the solution was concentrated under reduced pressure. Purification by flash chromatography (30% ethyl acetate in petroleum ether) gave a white foam (362 mg; 93).
%). Part of this material (100 mg; 0.203 mmo
l) was dissolved in absolute ethanol (20 mL) and placed in a flask equipped with a reflux condenser. Diisopropylethylamine (106_L; 0.609 mmol) followed by 2-mercapto-1-methylimidazole (70 mg;
0.609 mmol) was added and then the temperature was raised to reflux. After about 18 hours, the solution was cooled and then concentrated. Purification by flash chromatography (30% ethyl acetate in petroleum ether) gave the title compound as 98 mg of a white foam (87%).

C₂₉H₄₀N_FourO₃S₂・ 0.14 CH₂
Cl₂Analytical value as: Calculated value: C, 61.36; H, 7.12; N, 9.82 Actual value: C, 61.38; H, 7.03; N, 9.94 HPLC: (Vydac C18 Column; gradient 95
/ 5 to 0/100 H ₂O / CH₃CN, 0.1% T
FA-containing; 15-minute gradient, flow rate 1.5 mL / min) Rf
= 12.8 minutes Purity = 100%;¹ HNMR: Consistent with structure; FAB MS: m / z = 557 (M⁺+ H); Example 29

[0123]

[Chemical 52] Endo- (1S) dissolved in ethyl acetate (150 mL)
-1 '-(((2-amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H) -indan-1,4'-piperidine (801 mg. 1.99 mmol) in 1-Fm
oc- (DL) nipecotic acid (701 mg; 1.99 m)
mol), 1-hydroxybenzotriazole (269
mg; 1.99 mmol), and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (496 m)
g; 2.59 mmol) was added. After stirring for 18 hours at room temperature, the solution is poured into equal volumes of 1M NaOH, 1M HCl,
And washed successively with brine, dried over sodium sulfate, filtered and concentrated. Purification by flash chromatography (gradient: 30% ethyl acetate in petroleum ether to 50% ethyl acetate in petroleum ether) gave a white foam (1.18 g; 81%) which was then purified. It was dissolved in diethylamine (20 mL). 4 hours later,
The solution was concentrated under reduced pressure. Flash chromatography (gradient: 70% ethyl acetate in petroleum ether ~
Purification by 25% methanol dissolved in methylene chloride) gave the intermediate as a white foam (722 mg; 87%). Part of this foam (30 mg; 0.058 m
(mol) was dissolved in methylene chloride (12 mL). N,
N-dimethylglycine (10 mg; 0.070 mmo
1) followed by 1-hydroxybenzotriazole (9.5 mg; 0.070 mmol) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (14 mg; 0.075 mmol). After 5 hours, the mixture was concentrated and then partitioned between ethyl acetate (15 mL) and 1M NaOH (15 mL). The ethyl acetate solution was washed with brine, dried over sodium sulfate and then concentrated. Purified by preparative HPLC,
After lyophilization from 1,4-dioxane, 11 mg of the title compound was obtained as an amorphous solid (32%).

Analysis for C ₃₃ H ₅₀ N ₄ O ₄ S.1.88 TFA: Calculated: C, 54.29; H, 6.43; N, 6.89 Found: C, 54.32; H , 6.62; N, 6.68 HPLC: (Vydac C18 column; gradient 95
_{/ 5~0 / 100 H 2 O /} CH 3 CN, 0.1% T
FA-containing; 15-minute gradient, flow rate 1.5 mL / min) Rt
= 12.04 min Purity = 100%; ¹ HNMR: Consistent with structure; FAB MS: m / z = 599 (M ⁺ + H); Example 30.

[0125]

[Chemical 53] Hydrochloric end was dissolved in dry tetrahydrofuran (20 mL) in _{N 2 - (1S) -1 '} - (((2- (L-4-
Hydroxyprolinoylamino) -7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H) -indan-1,4′-piperidine (114 mg; 0.206 mmol) Solution of
Methanesulfonyl chloride (24 mL; 0.310 mmo
l), and pyridine (20 mL; 0.248 mmol)
Was added. After 4 hours at room temperature, the solution was concentrated, then ethyl acetate (100 mL) and 1M HCl (100 mL).
Distributed between. The ethyl acetate layer was dried over sodium sulfate and concentrated. Purification by flash chromatography (10% methanol dissolved in methylene chloride) gave the title compound (81 mg).

C ₂₉ H ₄₃ N ₃ O ₆ S ₂ · 0.10 H ₂ O
Analysis for: Calculated: C, 55.51; H, 6.80; N, 6.50 Found: C, 55.49; H, 6.82; N, 6.36 HPLC: (Vydac C18 column; Gradient 95
_{/ 5~0 / 100 H 2 O /} CH 3 CN, 0.1% T
FA-containing; 15-minute gradient, flow rate 1.5 mL / min) Rt
= 10.4 min Purity = 100%; ¹ HNMR: Consistent with structure; FAB MS: m / z = 594 (M ⁺ + H); Example 31 Endo- (1S) dissolved in methylene chloride (30 mL).
-1 '-(((2-amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H) -indane-1,4'-piperidine (270 mg. 0.689 mmol) in 1-hydroxybenzotriazole (136 mg; 1.03 m
mol), 1- (3-dimethylaminopropyl) -3-
Ethylcarbodiimide (193 mg; 1.03 mmo
1) and N-benzyloxycarbonyl-4-oxo-L-proline (270 mg; 1.0 mmol) were added. After 18 hours, the solution was concentrated and then partitioned between ethyl acetate (300 mL) and 1M HCl (300 mL). The organic layer was washed with 1 M NaOH (2 x 300 mL), dried over sodium sulfate and concentrated. Flash chromatography (5 dissolved in methylene chloride
% Methanol) to give the title compound (427m
g; 95%).

C ₃₆ H ₄₅ N ₃ O ₆ S.0.15 H ₂ O.
Analytical value for 0.15 CH ₂ Cl ₂ : Calcd: C, 65.46; H, 6.93; N, 6.34 Found: C, 65.47; H, 6.84; N, 6 .09 HPLC: (Vydac C18 column; gradient 95
_{/ 5~0 / 100 H 2 O /} CH 3 CN, 0.1% T
FA-containing; 15-minute gradient, flow rate 1.5 mL / min) Rt
= 14.51 min Purity = 100%; ¹ HNMR: Consistent with structure; FAB MS: m / z = 648 (M + + H); Example 32

[0128]

[Chemical 54] Endo- (1S) -dissolved in ethanol (20 mL)
1 '-(((2-amino-7,7-dimethylbicyclo (2.2.1) hept-1-yl) -methyl) sulfonyl) spiro (1H-indan-1,4'-piperidine)
To a solution of (94 mg; 0.17 mmol), N- (3-
Bromopropyl) phthalimide (69 mg; 0.255
mmol) followed by diisopropylethylamine (0.044 mL; 0.255 mmol).
The temperature was then raised to 50 ° C. After about 18 hours, the solution was cooled and concentrated under reduced pressure. The residue was converted to methylene chloride (1
50 mL) and dissolve in 1M HCl (2 x 150 mL)
Washed with water, dried over sodium sulfate and concentrated. Purify by flash chromatography (5% methanol in methylene chloride) to give the title compound (45 m
g; 40%) as a white solid.

C ₃₉ H ₅₀ N ₄ O ₆ S.0.10 H ₂ O.
0.15 CH ₂ analysis as Cl _2: Calculated: C, 65.54; H, 7.10 ; N, 7.81 Found: C, 65.52; H, 7.09 ; N, 7 .71 HPLC: (Vydac C18 column; gradient 95
_{/ 5~0 / 100 H 2 O /} CH 3 CN, 0.1% T
FA-containing; 15-minute gradient, flow rate 1.5 mL / min) Rt
= 13.81 min Purity = 100%; ¹ HNMR: Consistent with structure; FAB MS: m / z = 703 (M ⁺ + H); Table In addition to the compounds specifically exemplified above, the compounds of the present invention are Described in the table. These compounds are synthesized without undue experimentation using the above schemes, synthetic routes and methods described in the Examples, and variations well known to those skilled in the art. All the variants listed in the table below
It concerns the following general structural formulas:

[0130]

[Chemical 55] In the formula, R ¹ is hydrogen or hydroxy.

[0131]

[Chemical 56]

[0132]

[Chemical 57]

[0133]

[Chemical 58]

[0134]

[Chemical 59]

[0135]

[Chemical 60]

[0136]

[Chemical formula 61]

[0137]

[Chemical formula 62]

[0138]

[Chemical 63]

[0139]

[Chemical 64]

[0140]

[Chemical 65]

[0141]

[Chemical 66]

[0142]

[Chemical 67] Radiogland Binding Assays [ ³ H] oxytocin (OT) ([tyrosyl, 3,5-
[ ³ H] OT; 30-60 Ci / mmol]; New
England Nuclear. Boston, M
High affinity binding of A) to the uterine OT receptor was demonstrated by diethylstilbestol dipropionate (DES) treatment (0.
3 mg / kg, ip; 18-24) Based on assay ^* using crude uterine membrane preparations taken from rats. Competitive tests are based on the following assay buffer: 50 mM T
ris-HCl, 5 mM MgCl ₂ , and 0.1% B
It was carried out at equilibrium (60 min; 22 ° C.) with 1 nM [ ³ H] OT dissolved in SA, pH 7.4. Non-specific binding (10% of total binding) was measured using 1 μM unlabeled OT and the binding reaction was performed using a cell harvester (type 7019,
Skatron, Inc. , Sterling, VA)
It was terminated by filtering through a glass fiber filter with. IC ₅₀ (concentration of test compound that inhibits 0% OT) was reported unless otherwise stated.

[ ³ H] vasopressin (AVP) ([phenylalanyl-3,4,5) bound to crude membrane preparations of male rat liver (AVP-V ₁ site) or renal medulla (AVP-V ₂ site). ⁻³ H] AVP; 80 to 90 Ci / m
mol; New England Nuclear) was measured according to the method ^{** of} Butlen et al.
The competition assay is the following assay buffer: 100 mM
Tris-HCl, 5 mM MgCl ₂ , 0.1% BS
A, 1 nM [ ³ H] AVP (liver) or 2 nM [ ³ H] dissolved in 50 μM phenylmethylsulfonyl fluoride and 50 μg / ml bactracin, pH 8.0.
Equilibrium using AVP (kidney) (30 minutes at 30 ° C)
It was carried out in. Non-specific binding (5-10% of total binding)
The binding reaction was measured using 10 μM unlabeled AVP,
It was terminated by filtration as described above for the [ ³ H] OT binding assay.

The K _i value was calculated by using the K _d value obtained from the saturation binding assay and the IC ₅₀ value (K _i = IC _50/1 + c).
/ K _d ) ^*** was obtained for each compound from 3-6 separate measurements: [ ³ H] OT (uterine), 0.7 nM;
³ H] AVP (liver), 0.4 nM; [ ³ H] (kidney), 1.4 nM.

While this invention has been described and described with respect to a preferred embodiment, those skilled in the art will appreciate that various changes, modifications and substitutions are possible without departing from the spirit and scope of this invention. For example, effective doses other than the preferred doses described herein may be used to prevent preterm birth,
Alternatively, it may be applied to alter the responsiveness of the mammal to be treated for other indications to the compounds of the invention described above. Similarly, the specific pharmacological response observed was
It may depend on the particular active compound chosen, or on the presence or absence of a pharmaceutical carrier, and on the type of formulation and mode of administration used. Such anticipated changes or differences in outcome are anticipated depending upon the objectives and practice of the invention. Accordingly, the invention is limited only by the claims set forth below, and such claims as broadly construed are reasonable.

Continuation of the front page (51) Int.Cl. ⁵ Identification code Office reference number FI technical display location C07D 401/12 213 8829-4C 233 8829-4C 401/14 8829-4C // (C07D 401/12 207: 00 7019-4C 221: 00) 7431-4C (C07D 401/12 211: 00 9165-4C 221: 00) 7431-4C (C07D 401/12 213: 00 6701-4C 221: 00) 7431-4C (C07D 401 / 12 221: 00 7431-4C 233: 00) 7252-4C (C07D 401/14 221: 00 7431-4C 233: 00) 7252-4C (C07D 401/14 221: 00 7431-4C 233: 00 7252-4C 241 : 00) 8615-4C (C07D 401/14 221: 00 7431-4C 207: 00 7019-4C 209: 00) (72) Inventor Ben Evans USA, Pennsylvania 19446, Lansdale, Perchiomen Avenue 501 (72) Inventor Rothier M. Friideringer USA, Pennsylvania 19446, Landsdale, Newport Rain 744 (72) Inventor Kevin Gilbert United States, Pennsylvania 19503, Barry, Elm Street 665 (72) Inventor Doug Davryu Hobbs United States, Pennsylvania 19446, Landsdale, Garfield Avenir 843 (72) Inventor James B. Hotsoffman, USA, Pennsylvania 19406, King of Pracia, South Gulf Road, 606 (72) Inventor, George Ef Landel USA, Pennsylvania 19442, Blue Bell, Hover Road, 817 (72) ) Inventor Douglas Jay Petebone, Pennsylvania, 18914, Schalyfont, Hitzkorri Lane, 69, USA

Claims (6)

[Claims] 1. The following formula: [In the formula, R is H or alkylsulfonylalkyl, R ¹ is hydrogen or hydroxy, R ² is N- (R ³ ) ₂ , Het-R ⁴ or Alk-R ⁵
Wherein R ³ is independently one or more hydrogens; cycloalkyl; pyrrolidinyl substituted with oxo, carboxyalkyl or alkoxycarbonylalkyl; alkylamino, alkylcarbamate, alkylcarbonyl, Alkylsulfonyl, alkylthio, alkoxycarbonyl, amino, aminocarbonyl, carboxyl, dialkylamino, dialkylaminoaryl, hydroxyl, sulfhydryl, or substituted or unsubstituted heterocyclic 5 or 6 having 1 or 2 heteroatoms. A heterocycle (wherein the heteroatom is N and the ring substituent is alkalkoxycarbonyl), Het is 1 or 2 heteroatoms (wherein the heteroatom is N
Is a heterocyclic 5- or 6-membered ring having R ⁴ is alkylsulfonyl, alkylsulfonylamino, alkylsulfonyloxy, alkylaminocarbonyl, alkylcarbamate alkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonylalkyl, Aminoalkylcarbonyl,
Alalkoxycarbonyl, carbonyl, dialkylaminocarbonyl, dialkylaminoalkylcarbonyl, diaminoalkylcarbonyl, halogenalkyl,
Halogenalkylcarbonyl, halogenalkoxycarbonyl, hydroxy, hydroxyalkyl, hydroxyalkylcarbonyl, imidazolylalkylcarbonyl, imididinylalkylcarbonyl, or phthalimidinylalkyl, provided that for Het-R ⁴ , Het is alkoxycarbonyl, Alkoxycarbonylalkyl, alkalkoxycarbonyl, or hydroxy may not be monosubstituted, Alk is alkyl and R ⁵ is independently one or more R ⁶ or Het-R ⁷
Wherein R ⁶ is independently one or more alkyl carbamates; a substituted imidazolyl or pyrrolidinyl ring, wherein the ring substituents are alkyl or alkoxycarbonylalkyl, alkylcarbamate cycloalkyl, alkylcarbonylaminoalkyl. Sulfonyl, alkylimidazolylthio, alkylimidinidinylthio, alkylimidazolylalkylthio, alkylimidininylalkylthio, alkylpyrrolidinylthio,
Alkylpyrrolidinylalkylthio, alkylsulfonyl, alkylsulfonylamino, alkylsulfonylalkylamino, alkoxycarbonyl, alkoxycarbonylalkylamine, alkoxycarbonylalkylcarbonylamine, alkoxycarbonylalkylsulfonylamine, amino, aminocarbonyl, aminoalkylcarbonylamino, aminocarbonyl Alkylsulfonyl, aminocarbonylalkylcarbonylamino,
Alalkoxy, alalkoxycarbonyl, alalkylcarbamate, aryl carbamate, aryl carbamate carbonylamino, aryl carbamate alkylcarbonylamino, carboxyalkylamino,
Carboxyalkyl alkylcarbonylamino, carboxy alkylsulfonylamino, cyano, cyanoalkyl carbonyl, dialkylamino alkylcarbonylamino, or oxo in a) is an alkyl carbonyl amino substituted by, however, with respect to R ^6, R ⁶ is alkoxy It cannot be monosubstituted by any of carbonyl, alkyl carbamate, alkylsulfonyl, aralkyl carbamate, alalkoxy, amino, aminocarbonyl, or oxo; Het is as defined above; R ⁷ is one or more Alkyl; imidazolinylalkylcarbonyl; imidazolinylalkylcarbonylamino; oxo; pyrrolidinylalkylcarbonyl; one or more alkyl carbamates, alkyl carbamates Kill carbonyl, alkylsulfonylalkyl, amino, pyrrolidinylcarbonyl alkylcarbonylamino or alkylamino substituted by aralkyl alkoxyalkyl or oxo, provided that, Het-
For R ⁷ , Het is alkyl, alkylamino,
Cannot be monosubstituted by dialkylamino or oxo]
And a pharmaceutically acceptable salt thereof. 2. The following formula: [Wherein R ¹ is hydrogen or hydroxy, R ² is one of NH-R ³ , Het-R ⁴ , or Alk-R ⁵ , wherein R ³ is cycloalkyl; Pyrrolidinyl substituted by carboxyalkyl or alkoxycarbonylalkyl; alkyl carbamate, alkylcarbonyl, alkylsulfonyl, alkylthio, alkoxycarbonyl, amino, aminocarbonyl, carboxyl, hydroxyl, sulfhydryl, or substituted with 1 or 2 heteroatoms Or an alkyl substituted by an unsubstituted heterocyclic 5- or 6-membered ring wherein the heteroatom is N and the ring substituent is alkalkoxycarbonyl, and Het is a heteroatom A heterocyclic 5- or 6-membered ring having (wherein the heteroatom is N) And R ⁴ is alkylsulfonyl, alkylsulfonyloxy, alkylaminocarbonyl, alkylcarbamate alkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonylalkyl, aminoalkylcarbonyl, alkalkoxycarbonyl,
Carbonyl, dialkylaminocarbonyl, diaminoalkylcarbonyl, halogenalkyl, halogenalkoxycarbonyl, hydroxy, hydroxyalkyl, hydroxyalkylcarbonyl, imidazolylalkylcarbonyl, or phthalimidinylalkyl, provided that for Het-R ⁴ , Het is Alkoxycarbonyl, alkoxycarbonylalkyl, alkalkoxycarbonyl, or hydroxy may not be monosubstituted, Alk is alkyl and R ⁵ is independently one or more R ⁶ or Het-R ⁷
Wherein R ⁶ is independently one or more alkyl carbamates; a substituted imidazolyl or pyrrolidinyl ring, wherein the ring substituents are alkyl or alkoxycarbonylalkyl, alkylcarbamate cycloalkyl, alkylcarbonylaminoalkyl. Sulfonyl, alkylimidazolylthio, alkylimidazolylalkylthio, alkylpyrrolidinylthio, alkylpyrrolidinylalkylthio, alkylsulfonyl, alkylsulfonylamino, alkylsulfonylalkylamino, alkoxycarbonyl, alkoxycarbonylalkylamine, alkoxycarbonylalkylcarbonylamine, alkoxycarbonylalkyl Sulfonylamine, amino, aminocarbonyl, aminoalkylcarbonylamino, amino Rubonylalkylsulfonyl, aminocarbonylalkylcarbonylamino, alalkoxy, alalkoxycarbonyl, alalkylcarbamate, arylcarbamate, arylcarbamatecarbonylamino, arylcarbamatealkylcarbonylamino, carboxyalkylamino, carboxyalkylcarbonylamino, carboxyalkylsulfonylamino, cyano , Cyanoalkylcarbonylamino, dialkylaminoalkylcarbonylamino, or oxo), provided that for R ⁶ , R ⁶ is alkoxycarbonyl, alkylcarbamate, alkylsulfonyl, aralkylcarbamate. , Alalkoxy, amino, aminocarbonyl, or oxo Re not give monosubstituted by either; Het is defined as above; R
⁷ is one or more alkyl; imidazolinylalkylcarbonyl; imidazolinylalkylcarbonylamino; oxo; pyrrolidinylalkylcarbonyl; one or more alkylcarbamate, alkylcarbamatealkylcarbonyl, alkylsulfonylalkyl, Pyrrolidinylalkylcarbonylamino or alkylamino substituted by amino, alkalkoxyalkyl or oxo, provided that Het cannot be monosubstituted by alkyl, alkylamino, dialkylamino or oxo for Het-R ⁷ . And a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising a compound according to claim 1 in an amount sufficient to antagonize the binding of oxytocin to the receptor site of oxytocin and a pharmaceutically acceptable carrier. 4. A pharmaceutical composition comprising a compound of claim 1 in an amount sufficient to prevent preterm birth in mammals and a pharmaceutically acceptable carrier. 5. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier in an amount sufficient to stop delivery prior to cesarean section in a mammal. 6. A pharmaceutical composition comprising a compound of claim 1 in an amount sufficient to treat dysmenorrhea and a pharmaceutically acceptable carrier.